The value of FDG PET/CT in the management of malignant melanoma: a retrospective study

Year 2022, Volume: 8 Issue: 3, 333 - 339, 04.05.2022

Alev Çınar , Semra Ince , Ülkü Nur Göker

https://doi.org/10.18621/eurj.891945

Abstract

Objectives: Positron Emission Tomography with Computed Tomography (PET/CT) is a valuable imaging method for the restaging of malignant diseases as well as the evaluation of treatment outcomes. Malignant melanoma is an aggressive tumor. Surgical resection is the primary treatment. As melanoma lesions are mostly FDG-avid, whole-body 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging modality can be used to determine the spread of the tumor. In the present study, we intended to share our clinical experience with FDG PET/CT in malignant melanoma patients under different kinds of treatment.

Methods: In this retrospective study, the data sets of 122 patients who had surgical resection of known primary tumors, all of which were histopathology-proven malignant melanoma, were analyzed. All patients underwent baseline 18F-FDG PET/CT scan no sooner than 45 days and at least once after surgery. Clinical information, radiological imaging, histopathology, and treatment modalities were noted for all patients, and 18F-FDG PET/CT findings were examined.

Results: All patients were histopathology-proven and 47 of them had acral lentiginous, 37 nodular, 23 amelanotic, and 15 atypical malignant melanoma. Local recurrence was detected by 18F-FDG PET/CT in 13 (10.6%; 3 male, 10 female) of the 122 patients, and the mean recurrence time after diagnosis was 3 ± 1.4 years. 10 patients with brain and bone metastases underwent radiotherapy. 19 patients with lung, bone, and hepatic metastases received chemotherapy and 22 patients immunotherapy.

Conclusions: Malignant melanoma is a type of skin cancer that may involve any organ. In localized cases, complete surgical resection may be adequate for a cure. If diagnosed with the latter type, the whole body of the patient must be examined.

Keywords

FDG PET/CT, malignant melanoma, postoperative recurrence, restaging

References

• 1. Roses DF, Karp NS, Oratz R, Dubin N, Harris MN, Speyer J, et al. Survival with regional and distant metastases from cutaneous malignant melanoma. Surg Gynecol Obstet 1991;172:262-8.
• 2. Reinhardt MJ, Joe, AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole-body 18FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24:1178-87.
• 3. Malik D, Sood A, Mittal BR, Basher RK, Bhattacharya A, Singh G. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in restaging and prognosis of recurrent melanoma after curative surgery. World J Nucl Med 2019;18:176.
• 4. Garcia GA, Fernandez F, Satue E, Buelta L, Val-Bernal J. Metastasis of malignant neoplasms of skeletal muscle. Rev Esp Oncol 1984;31:57-67.
• 5. Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 2018;45:376-83.
• 6. Herring CL, Harrerlson JM, Scully SP. Metastatic melanoma with an unknown primary. Br J Plast Surg 1990;43:367-8.
• 7. Portilla G, Cruz A, Juan N, Malo P, Lopez de Heredia E, Larrañaga M, et al. Isolated rectus abdominis metastasis from melanoma, an extremely rare case. Int J Surg Case Rep 2016;26:121-3.
• 8. Gillgren P, Månsson-Brahme E, Frisell J, Johansson H, Larsson O, Ringborg U. Epidemiological characteristics of cutaneous malignant melanoma of the head and neck--a population-based study. Acta Oncol 1999;38:1069-74.
• 9. Brountzos E, Panagiotou I, Bafaloukos D, Kelikis D. Bone metastases from malignant melanoma; a retrospective review and analysis of 28 cases. Radiol Oncol 2001;35:209-14.
• 10. Bastiaannet E, Oyen WJ, Meijer S, Hoekstra OS, Wobbes T, Jager PL, et al. Impact of [18F] fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients. Br J Surg 2006;93:243-9.
• 11. Schumacher TN, Schreiber RD. Neo antigens in cancer immunotherapy. Science 2015;348:69-74.
• 12. Sadozai H, Gruber T, Hunger RE, Schenk M. Recent successes and future directions in immunotherapy of cutaneous melanoma. Front Immunol 2017;8:1617.
• 13. Tawbi HAH, Forsyth PA, Algazi AP, Hamid O, Hodi FS, Moschos SJ, et al. Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the braIn: Results of the phase II study CheckMate 204. J Clin Oncol 2017;35(Suppl):9507.
• 14. Gutman F, Alberini JL, Wartski, M, Vilain D, Le Stanc E, Sarandi F, et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol 2005;185:495-500.